BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23312891)

  • 1. The impact of socioeconomic status on prostate cancer treatment and survival in the southern Netherlands.
    Aarts MJ; Koldewijn EL; Poortmans PM; Coebergh JW; Louwman M
    Urology; 2013 Mar; 81(3):593-9. PubMed ID: 23312891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Socioeconomic inequalities in attending the mass screening for breast cancer in the south of the Netherlands--associations with stage at diagnosis and survival.
    Aarts MJ; Voogd AC; Duijm LE; Coebergh JW; Louwman WJ
    Breast Cancer Res Treat; 2011 Jul; 128(2):517-25. PubMed ID: 21290176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of socioeconomic status on staging and treatment decisions in esophageal cancer.
    Bus P; Aarts MJ; Lemmens VE; van Oijen MG; Creemers GJ; Nieuwenhuijzen GA; van Baal JW; Siersema PD
    J Clin Gastroenterol; 2012; 46(10):833-9. PubMed ID: 22460163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer.
    Berglund A; Garmo H; Robinson D; Tishelman C; Holmberg L; Bratt O; Adolfsson J; Stattin P; Lambe M
    Eur J Cancer; 2012 Jan; 48(1):75-84. PubMed ID: 21852113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis.
    Rapiti E; Fioretta G; Schaffar R; Neyroud-Caspar I; Verkooijen HM; Schmidlin F; Miralbell R; Zanetti R; Bouchardy C
    Cancer; 2009 Dec; 115(23):5556-65. PubMed ID: 19787636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short- and long-term mortality with localized prostate cancer.
    Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
    Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Socioeconomic status and comorbidity among newly diagnosed cancer patients.
    Schrijvers CT; Coebergh JW; Mackenbach JP
    Cancer; 1997 Oct; 80(8):1482-8. PubMed ID: 9338473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of socioeconomic status on survival after cancer in the United States : findings from the National Program of Cancer Registries Patterns of Care Study.
    Byers TE; Wolf HJ; Bauer KR; Bolick-Aldrich S; Chen VW; Finch JL; Fulton JP; Schymura MJ; Shen T; Van Heest S; Yin X;
    Cancer; 2008 Aug; 113(3):582-91. PubMed ID: 18613122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
    Zietman AL; Thakral H; Wilson L; Schellhammer P
    J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
    Rosenberg JE; Chen MH; Nguyen PL; Braccioforte MH; Moran BJ; D'Amico AV
    Clin Genitourin Cancer; 2012 Mar; 10(1):21-5. PubMed ID: 22130293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor size.
    Bastiaannet E; de Craen AJ; Kuppen PJ; Aarts MJ; van der Geest LG; van de Velde CJ; Westendorp RG; Liefers GJ
    Breast Cancer Res Treat; 2011 Jun; 127(3):721-7. PubMed ID: 21076863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study.
    Abdollah F; Sun M; Schmitges J; Thuret R; Tian Z; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):95-103. PubMed ID: 22330991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study.
    Houterman S; Janssen-Heijnen ML; Verheij CD; Kil PJ; van den Berg HA; Coebergh JW
    Prostate Cancer Prostatic Dis; 2006; 9(2):179-84. PubMed ID: 16534509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
    Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
    J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE.
    Konety BR; Cowan JE; Carroll PR;
    J Urol; 2008 May; 179(5):1797-803; discussion 1803. PubMed ID: 18343440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.